Clinical Results Behind Metanx®

Doctor holding a piece of paper while sitting with a patient, indicating a consultation or discussion.

Proven efficacy, patient satisfaction & safety

Over 15 years of clinical studies on the Metanx® formula† demonstrate the benefits of 3 key nutrients found in MetanxPRO Nerve Health™. These 3 bioactive ingredients have been proven effective in patients with diabetic peripheral neuropathy (DPN) at improving nerve density and function and providing symptom relief.

Talk to a Metanx® Rep

Regeneration of epidermal nerve fibers seen after 6 months

In a clinical study, Metanx®† significantly increased nerve fiber density by 97% after 6 months of use in patients with DPN and small-fiber neuropathy (P = 0.004; N = 11).7

Before

Microscopic image of a skin punch biopsy with nerve fibers labeled, on a light gray background.

After taking Metanx® for 6 months

Microscopic view of skin tissue with nerve fibers labeled, showing a 97% increase in density.
Images courtesy of Therapath Partners, LLC. Used with permission§

Benefits Shown in DPN Patients After 12 weeks of Metanx®†

Bar chart showing symptom reduction percentages over time with baseline and 12-week measurements.

Results of patients with DPN who were prescribed Metanx FC™(N=544) and completed a survey before and after 12 weeks in a real-world study.4

Acetyl-L-carnitine expands clinical foundation in
MetanxPRO Nerve Health™

Multiple clinical studies on acetyl-L-carnitine showed the following results:

Reduction in nerve discomfort associated with pain in as early as 14 days1

Reduction in pain within 3 weeks in patients with PN due to HIV-antiretroviral toxic neuropathy2

Decrease in symptom severity within 14 days for patients with chemotherapy-induced PN3

Real-world patients and the benefits of Metanx® nutritional support

Actual results may vary. Individual results are dependent on various factors including personal health, genetics, adherence to prescribed medications and other personal circumstances.

DPN with Raynaud’s disease case study

A 57-year-old male patient with insulin-dependent type 1 diabetes mellitus reported numbness in his feet, burning skin changes, and non-blanchable erythema consistent with Raynaud’s disease.

Prescribed METANX† (1 capsule BID).

Patient-reported outcomes:

  • Following 1 month of METANX† use, the patient reported a decrease in burning and tingling in his feet.
  • At 3 months, the patient reported a reduction in numbness and resolution of the burning sensation. The patient’s skin also showed decreased erythema from the initial visit and is now blanchable.

Patient case provided by Dr Eric S. Trathen, DPM. Fort Myers, Florida

Chemotherapy-induced PN† case study

A 69-year-old female patient with colon cancer reported significant pain and numbness in her hands and feet following chemotherapy.

Prescribed METANX* (1 capsule BID) alongside a neuropathy medication.

Patient-reported outcomes:

  • Following 1 month of METANX* use, the patient reported a 50% reduction in pain in both her hands and feet.
  • At 2 months, the pain in her hands had resolved, and the foot pain had decreased further.
  • After 11 months of METANX* use, the pain in her hands and feet had resolved completely, with minor numbness only in her toes.

Patient case provided by Dr Eric S. Trathen, DPM. Fort Myers, Florida